vTv Therapeutics Inc. (VTVT)

3.74 +0.39 (+11.642%)

IEX Real-Time Price

October 19, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 3.35

Price Open 3.4

Volume: 3.22M

Avg Volume: 5.77M

Market Cap: 145.36M

P/E Ratio -2.65

52 Wk Range 0.65-8.4



VTVT Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-09-28
38.75M
706,355
4.97
1.82%

2018-09-14
36.87M
727,469
6.82
1.97%

2018-08-31
36.87M
729,673
11.82
1.98%

2018-08-15
34.99M
742,466
11.00
2.12%




VTVT Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-03
Q2 2018
N/A
-0.25 (3)
-0.29
-0.04

2018-05-15
Q1 2018
N/A
-0.35 (3)
-0.30
0.05

2018-05-02
Q1 2018
N/A
-0.41 (2)
0.00
0.00

2018-02-27
Q4 2017
N/A
-0.41 (3)
-0.44
-0.03

News

Key events next week - healthcare (2018-10-19 11:08 SeekingAlpha)

Noteworthy events during the week of October 21 - 27 for healthcare investors. More news on: Alpine Immune Sciences, Inc., NovoCure, ViewRay, Healthcare stocks news, , Read more …

 


Statistics

Shares Outstanding: 38.87M

Top 15 Institution Percent: 84.80

Price To Sales: 27.30

Price To Book: N/A

Revenue: 15000

Gross Profit: N/A

Cash: 20.49M

Debt: 19.31M

Return On Assets: -59.50

Return On Equity: 15.71

Profit Margin: N/A

Price History

Beta: -4.15

50-day Moving Avg: 1.60

200-day Moving Avg: 2.99

YTD Change: -38.28

5-day Change: 28.08

1-month Change: N/A

3-month Change: 157.93

6-month Change: 70.00

1-year Change: -48.77

Revenue Per Share: 0.00

Revenue Per Employee: 268.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: vTv Therapeutics Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.vtvtherapeutics.com

vTv Therapeutics Inc is a biopharmaceutical company engaged in drug discovery and development. Its therapies are intended to treat diseases such as Alzheimer's and type-II diabetes. Its other products include TTP399, type II diabetes drug candidate.